Case number 2021-1924
UCB, Inc. v. Actavis Laboratories UT, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 18, 2023 | 0 | UCB, INC. v. ACTAVIS LABORATORIES UT, INC. [ERRATA] [nonprecedential] (0) |
| Jun 16, 2023 | 73 | Mandate issued to the United States District Court for the District of Delaware; the United States District Court for the District of Vermont. Service as of this date by the Clerk of Court. [930523] [21-1924, 21-2336] [MVH] [Entered: 06/16/2023 09:55 AM] (2) |
| Jun 16, 2023 | 72 | ERRATA to Precedential Opinion Doc No. [65], Judgment [66], and order [68]. Service as of this date by the Clerk of Court. [930522] [21-1924, 21-2336] [MVH] [Entered: 06/16/2023 09:50 AM] (2) |
| Jun 16, 2023 | 71 | ORDER filed recalling mandate. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [930521] [21-1924, 21-2336] [MVH] [Entered: 06/16/2023 09:47 AM] (2) |
| May 26, 2023 | 70 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [926105] [21-1924, 21-2336]. Mandate has been recalled pursuant to the court's order. See Doc. No. [71] [MVH] [Entered: 05/26/2023 09:46 AM] (2) |
| May 8, 2023 | 68 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [67] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH. Petition for Rehearing due on or before 05/19/2023. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [921770]. Errata issued. See Doc. No. [72]--[Edited 06/16/2023 by MVH] [MVH] [Entered: 05/08/2023 11:14 AM] (2) |
| May 5, 2023 | 67 | MOTION of Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc. to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 05/19/2023. Service: 05/05/2023 by email. [921432] [21-1924] [Richard Rainey] [Entered: 05/05/2023 11:01 AM] (7) |
| Apr 16, 2023 | 0 | UCB, INC. v. ACTAVIS LABORATORIES UT, INC. [OPINION] [precedential] (0) |
| Apr 12, 2023 | 66 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [916180] [21-1924, 21-2336]. Errata issued. See Doc. No. [72]--[Edited 06/16/2023 by MVH] [MVH] [Entered: 04/12/2023 10:36 AM] (2) |
| Apr 12, 2023 | 65 | OPINION filed for the court by Moore, Chief Judge; Chen, Circuit Judge and Stoll, Circuit Judge. Precedential Opinion. Service as of this date by the Clerk of Court. [916179] [21-1924, 21-2336]. Errata issued. See Doc. No. [72]--[Edited 06/16/2023 by MVH] [MVH] [Entered: 04/12/2023 10:35 AM] (28) |
| Oct 4, 2022 | 64 | Submitted after ORAL ARGUMENT to Panel: Moore, Chief Judge; Chen, Circuit Judge and Stoll, Circuit Judge.Arguing counsel: Richard L. Rainey for UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH and John C. O'Quinn for Actavis Laboratories UT, Inc.Oral Argument Audio available here. [875604] [MJL] [Entered: 10/04/2022 10:17 AM] (0) |
| Aug 30, 2022 | 63 | Response to notice of oral argument from Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc.. Service: 08/30/2022 by email. [869089] [21-1924] [John O'Quinn] [Entered: 08/30/2022 07:45 PM] (3) |
| Aug 26, 2022 | 62 | Response to notice of oral argument from Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 08/26/2022 by email. [868534] [21-1924] [Richard Rainey] [Entered: 08/26/2022 06:02 PM] (3) |
| Aug 22, 2022 | 61 | NOTICE OF ORAL ARGUMENT. Panel: 2210D. Case scheduled October 4, 2022. Response to Notice of Oral Argument due: 09/06/2022. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [867627] [MVH] [Entered: 08/22/2022 02:46 PM] (2) |
| Aug 5, 2022 | 60 | 6 paper copies of Doc. No. [57] received from Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. [865229] [VDW] [Entered: 08/05/2022 03:25 PM] (0) |
| Jul 29, 2022 | 59 | Notice of Correction to Doc No. [49], [48] for Appellants UCB Pharma GmbH, UCB, Inc. and LTS Lohmann Therapie-Systeme AG. Service: 07/29/2022 by email. [863855] [21-1924] [Richard Rainey] [Entered: 07/29/2022 01:35 PM] (6) |
| Jul 29, 2022 | 58 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, UCB, Inc. and Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc. Service: 07/29/2022 by email. [863849]--[Edited 08/03/2022 by EKD - compliance review complete] [Richard Rainey] [Entered: 07/29/2022 01:25 PM] (948) |
| Jul 29, 2022 | 57 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, UCB, Inc. and Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc. Service: 07/29/2022 by email. [863847]--[Edited 08/03/2022 by EKD - compliance review complete] Paper copies of the corrected appendix must be submitted within five business days from the date of issuance of this notice--[Edited 08/03/2022 by EKD to add note] [Richard Rainey] [Entered: 07/29/2022 01:21 PM] (0) |
| Apr 14, 2022 | 56 | Notice from Appellee Actavis Laboratories UT, Inc. regarding conflicts with oral argument. Service: 04/14/2022 by email. [843321] [21-1924] [John O'Quinn] [Entered: 04/14/2022 06:51 PM] (1) |
| Apr 13, 2022 | 55 | 6 paper copies of Doc. No. [38] received from Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc.. [843196] [VDW] [Entered: 04/14/2022 02:26 PM] (0) |
| Apr 12, 2022 | 54 | 6 paper copies of Doc. No. [49], [43], [35] received from Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. [842639] [VDW] [Entered: 04/12/2022 04:39 PM] (0) |
| Apr 12, 2022 | 53 | The following conflict dates submitted by Richard L. Rainey for UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH have been accepted by the court: 07/05/2022, 07/06/2022, 07/07/2022, 07/08/2022, 08/04/2022, 08/05/2022. [842538] [MJL] [Entered: 04/12/2022 09:40 AM] (0) |
| Apr 11, 2022 | 52 | Notice from Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG regarding conflicts with oral argument. Service: 04/11/2022 by email. [842424] [21-1924] [Richard Rainey] [Entered: 04/11/2022 03:19 PM] (4) |
| Apr 7, 2022 | 51 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [841632] [EKD] [Entered: 04/07/2022 11:30 AM] (1) |
| Apr 7, 2022 | 50 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [841631] [EKD] [Entered: 04/07/2022 11:30 AM] (0) |
| Apr 6, 2022 | 49 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc. Service: 04/06/2022 by email. [841528]--[Edited 04/07/2022 by EKD - compliance review complete] This document has been corrected. See Doc No. [57] [Richard Rainey] [Entered: 04/06/2022 11:33 PM] (0) |
| Apr 6, 2022 | 48 | MODIFIED ENTRY: APPENDIX FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 04/06/2022 by email. [841527] --[Edited 04/07/2022 by EKD - compliance review complete] This document has been corrected. See Doc No. [58] [Richard Rainey] [Entered: 04/06/2022 11:29 PM] (927) |
| Apr 6, 2022 | 47 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellee Mylan Technologies Inc.. Service: 04/06/2022 by email. [841508] [21-1924] [Deepro Mukerjee] [Entered: 04/06/2022 07:30 PM] (2) |
| Apr 6, 2022 | 46 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 04/06/2022 by email. [841505] [21-1924] [Richard Rainey] [Entered: 04/06/2022 06:45 PM] (3) |
| Apr 5, 2022 | 45 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellee Actavis Laboratories UT, Inc.. Service: 04/05/2022 by email. [841242] [21-1924] [William Burgess] [Entered: 04/05/2022 10:25 PM] (1) |
| Apr 5, 2022 | 44 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 04/05/2022 by email. [841222] [21-1924] [Michael Bowlus] [Entered: 04/05/2022 05:41 PM] (3) |
| Mar 30, 2022 | 43 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, and UCB, Inc. Service: 03/30/2022 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [840023] --[Edited 03/31/2022 by EKD - compliance review complete] [Richard Rainey] [Entered: 03/30/2022 06:37 PM] (41) |
| Feb 11, 2022 | 42 | **TEXT ONLY** ORDER granting motion to extend time to file brief [41] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH. The reply brief is due 03/30/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [830752] [JCW] [Entered: 02/11/2022 03:24 PM] (0) |
| Feb 11, 2022 | 41 | MOTION of Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG to extend the time to 03/30/2022 to file brief. Service: 02/11/2022 by email. [830707] [21-1924] [Richard Rainey] [Entered: 02/11/2022 02:29 PM] (10) |
| Feb 10, 2022 | 40 | Corrected Entry of appearance for John C. O'Quinn; William H. Burgess; Christopher T. Jagoe; Thomas F. Fleming; Tera J. Stone as counsel for Appellee Actavis Laboratories UT, Inc.. Service: 02/10/2022 by email. [830474] [21-1924] [William Burgess] [Entered: 02/10/2022 04:06 PM] (2) |
| Feb 8, 2022 | 39 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Actavis Laboratories UT, Inc., Entry of Appearance [36], is not in compliance with the rules of this court (see attached). Compliant document is due on 02/15/2022. Service as of this date by the Clerk of Court. [829606] [EKD] [Entered: 02/08/2022 09:06 AM] (1) |
| Feb 7, 2022 | 37 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc. Service: 02/07/2022 by email. [829520] --[Edited 02/14/2022 by EKD - compliance review complete] [John O'Quinn] [Entered: 02/07/2022 05:48 PM] (90) |
| Feb 7, 2022 | 38 | MODIFIED ENTRY: CONFIDENTIAL RESPONSE BRIEF FILED by Appellees Actavis Laboratories UT, Inc. and Mylan Technologies Inc. Service: 02/07/2022 by email. [829521]--[Edited 02/14/2022 by EKD - compliance review complete] [John O'Quinn] [Entered: 02/07/2022 05:50 PM] (0) |
| Feb 7, 2022 | 36 | Amended Entry of appearance for John C. O'Quinn; William H. Burgess; Christopher T. Jagoe; Thomas F. Fleming; Tera J. Stone as counsel for Appellee Actavis Laboratories UT, Inc.. Service: 02/07/2022 by email. [829517] [21-1924] This document is non-compliant. See Doc No. [39] [William Burgess] [Entered: 02/07/2022 05:45 PM] (2) |
| Jan 11, 2022 | 35 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, and UCB, Inc. Service: 01/11/2022 by email. [823850]--[Edited 01/12/2022 by EKD - compliance review complete] [Richard Rainey] [Entered: 01/11/2022 02:07 PM] (0) |
| Jan 11, 2022 | 34 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, and UCB, Inc. Service: 01/11/2022 by email. [823844]--[Edited 01/12/2022 by EKD - compliance review complete] [Richard Rainey] [Entered: 01/11/2022 02:00 PM] (179) |
| Jan 11, 2022 | 33 | Amended Certificate of Interest for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 01/11/2022 by email. [823838] [21-1924] [Richard Rainey] [Entered: 01/11/2022 01:52 PM] (4) |
| Jan 4, 2022 | 32 | NOTICE OF NON-COMPLIANCE: The submission of Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc., Opening Brief; Confidential Opening Brief [29], [30], is not in compliance with the rules of this court (see attached). Compliant documents due on 01/11/2022. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [822479] [MMA] [Entered: 01/04/2022 10:23 AM] (1) |
| Jan 4, 2022 | 31 | ORDER denying as moot motion for a word enlargement [27] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH. Service as of this date by the Clerk of Court. [822438] [LMS] [Entered: 01/04/2022 08:07 AM] (2) |
| Dec 29, 2021 | 30 | CONFIDENTIAL OPENING BRIEF FILED by Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 12/29/2021 by email. [821884] [21-1924] This document is non-compliant. See Doc No. [32] [Richard Rainey] [Entered: 12/29/2021 06:38 PM] (0) |
| Dec 29, 2021 | 29 | OPENING BRIEF FILED by Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 12/29/2021 by email. [821883] [21-1924] This document is non-compliant. See Doc No. [32] [Richard Rainey] [Entered: 12/29/2021 06:29 PM] (180) |
| Dec 27, 2021 | 28 | Letter from Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG Requesting Decision on Pending Motion to Extend Type-Volume Limitation for Replacement Opening Brief. Service: 12/27/2021 by email. [821416] [21-1924] [Richard Rainey] [Entered: 12/27/2021 09:42 PM] (1) |
| Dec 9, 2021 | 27 | MOTION of Appellants UCB Pharma GmbH, UCB, Inc. and LTS Lohmann Therapie-Systeme AG to Enlarge Type-Volume Limitation for Replacement Opening Brief. Service: 12/09/2021 by email. [817456] [21-1924] [Richard Rainey] [Entered: 12/09/2021 12:47 PM] (9) |
| Nov 19, 2021 | 26 | Note to File: The following cases are consolidated: 21-1924 Lead with 21-2336 Consolidated Member Case. The parties must file all documents in the lead appeal only. [816778] [21-1924, 21-2336] [EKD] [Entered: 12/07/2021 12:14 PM] (0) |
| Nov 19, 2021 | 25 | ORDER filed. The motion [810331-2] is granted to the extent that the appeals (21-1924 and 21-2336) are consolidated. The revised official caption and short caption are reflected in the order. UCB's motion [810768-2] is denied. Within 40 days of the date of filing of this order, UCB is directed to file a replacement opening brief addressing the consolidated appeals. (see order for details). (Per Curiam). Service as of this date by the Clerk of Court. [813664] [21-2336, 21-1924] [NL] [Entered: 11/19/2021 12:21 PM] (3) |
| Sep 30, 2021 | 24 | Amended Entry of appearance for Richard L. Rainey; James S. Trainor; Brian G. Bieluch; Michael E. Bowlus as counsel for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 09/30/2021 by email. [802903] [21-1924] [Richard Rainey] [Entered: 09/30/2021 03:50 PM] (2) |
| Sep 14, 2021 | 23 | ORDER granting motion to extend time to file brief [22] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and Appellee Actavis Laboratories UT, Inc. The response brief is due 12/06/2021. The reply brief is due 01/27/2022. Service as of this date by the Clerk of Court. [799228] [LMS] [Entered: 09/14/2021 03:32 PM] (2) |
| Sep 13, 2021 | 22 | MOTION of Appellee Actavis Laboratories UT, Inc. and Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc. to extend the time to 12/06/2021 to file brief, to extend the time to file brief. Service: 09/13/2021 by email. [798723] [21-1924] [John O'Quinn] [Entered: 09/13/2021 11:38 AM] (10) |
| Sep 7, 2021 | 21 | Notice from Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc. Withdrawal of Alaina Whitt as Counsel. Service: 09/07/2021 by email. [797525] [21-1924] [Alaina Whitt] [Entered: 09/07/2021 03:22 PM] (3) |
| Sep 2, 2021 | 20 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, and UCB, Inc. Service: 09/02/2021 by email. [796910]--[Edited 09/02/2021 by EKD - compliance review complete] [James Trainor] [Entered: 09/02/2021 01:56 PM] (0) |
| Sep 2, 2021 | 19 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH, and UCB, Inc. Service: 09/02/2021 by email. [796909] --[Edited 09/02/2021 by EKD - compliance review complete] [James Trainor] [Entered: 09/02/2021 01:54 PM] (163) |
| Sep 2, 2021 | 18 | Notice of Correction to Doc No. [17], [16] for Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 09/02/2021 by email. [796908] [21-1924] [James Trainor] [Entered: 09/02/2021 01:52 PM] (6) |
| Aug 26, 2021 | 17 | CONFIDENTIAL OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 08/26/2021 by email. [795595] [21-1924] This document has been corrected. See Doc No. [20] [James Trainor] [Entered: 08/26/2021 05:06 PM] (0) |
| Aug 26, 2021 | 16 | OPENING BRIEF FILED by Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 08/26/2021 by email. [795594] [21-1924] This document has been corrected. See Doc No. [19] [James Trainor] [Entered: 08/26/2021 05:05 PM] (163) |
| Jul 29, 2021 | 15 | **TEXT ONLY** ORDER granting motion to extend time to file brief [14] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG and UCB Pharma GmbH. The opening brief is due 08/26/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [789319] [JCW] [Entered: 07/29/2021 10:03 AM] (0) |
| Jul 28, 2021 | 14 | MOTION of Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG to extend the time to 08/26/2021 to file brief. Service: 07/28/2021 by email. [789156] [21-1924] [James Trainor] [Entered: 07/28/2021 01:18 PM] (7) |
| Jun 15, 2021 | 13 | Entry of appearance for Anthony D. Raucci as counsel for Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 06/15/2021 by email. [780439] [21-1924] [Anthony Raucci] [Entered: 06/15/2021 02:56 PM] (1) |
| Jun 1, 2021 | 12 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [10], ERROR: The Certificate of Interest is incomplete. CORRECTION: For future filings, please include Question #6. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [777755] [EKD] [Entered: 06/01/2021 08:58 AM] (0) |
| Jun 1, 2021 | 11 | **TEXT ONLY** ORDER granting motion to extend time to file brief [10] filed by Appellants UCB, Inc., LTS Lohmann Therapie-Systeme AG, and UCB Pharma GmbH. The opening brief is due 08/05/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [777754] [EKD] [Entered: 06/01/2021 08:56 AM] (0) |
| May 28, 2021 | 10 | MOTION of Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG to extend the time to 08/05/2021 to file brief. Service: 05/28/2021 by email. [777665] [21-1924] [James Trainor] [Entered: 05/28/2021 04:09 PM] (6) |
| May 21, 2021 | 9 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [6], Doc No. [7], Doc No. [8], ERROR: The documents contain non-compliant signatures. CORRECTION: For future filings, please use an electronic signature consisting of the printed name of the individual preceded by the mark /s/ entered on the signature line. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [776405] [EKD] [Entered: 05/21/2021 09:33 AM] (0) |
| May 20, 2021 | 8 | Docketing Statement for the Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 05/20/2021 by email. [776367] [21-1924] [James Trainor] [Entered: 05/20/2021 05:35 PM] (3) |
| May 20, 2021 | 7 | Certificate of Interest for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 05/20/2021 by email. [776366] [21-1924] [James Trainor] [Entered: 05/20/2021 05:29 PM] (5) |
| May 20, 2021 | 6 | Entry of appearance for James S. Trainor; Kevin X. McGann; Silvia M. Medina; Catherine H. McCord; Jack B. Blumenfeld; Derek J. Fahnestock as counsel for Appellants UCB, Inc., UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG. Service: 05/20/2021 by email. [776360] [21-1924] [James Trainor] [Entered: 05/20/2021 05:18 PM] (3) |
| May 20, 2021 | 5 | Entry of appearance for George Frank Pappas; Richard L. Rainey; Alexa Hansen; Alaina Marie Whitt as counsel for Appellants LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbH and UCB, Inc.. Service: 05/20/2021 by email. [776268] [21-1924] [Alaina Whitt] [Entered: 05/20/2021 02:24 PM] (2) |
| May 20, 2021 | 4 | Docketing Statement for the Appellee Actavis Laboratories UT, Inc.. Service: 05/20/2021 by email. [776198] [21-1924] [William Burgess] [Entered: 05/20/2021 11:25 AM] (2) |
| May 20, 2021 | 3 | Certificate of Interest for Appellee Actavis Laboratories UT, Inc.. Service: 05/20/2021 by email. [776197] [21-1924] [William Burgess] [Entered: 05/20/2021 11:25 AM] (2) |
| May 20, 2021 | 2 | Entry of appearance for John C. O'Quinn; William H. Burgess; Christopher T. Jagoe; Thomas F. Fleming as counsel for Appellee Actavis Laboratories UT, Inc.. Service: 05/20/2021 by email. [776196] [21-1924] [William Burgess] [Entered: 05/20/2021 11:23 AM] (2) |
| May 6, 2021 | 1 | Appeal docketed. Received: 05/03/2021. [773389]Entry of Appearance is due on 05/20/2021. Certificate of Interest is due on 05/20/2021. Docketing Statement is due on 05/20/2021. Appellants' brief is due on 07/06/2021. [EKD] [Entered: 05/06/2021 12:57 PM] (28) |
